Recipient and donor CMV serostatus and outcome following nonmyeloablative transplantation among patients at risk of CMV disease*
| CMV serostatus . | CMV infection (%) . | Recurrence < 100 d (%) . | Recurrence > 100 d (%) . | CMV disease (%) . | Nonrelapse mortality . | |
|---|---|---|---|---|---|---|
| 100 d (%) . | Overall (%) . | |||||
| R+/D+ | 35/38 (92) | 16/27 (59) | 9/24 (41) | 2/38 (5.2) | 3 (7.8) | 7 (18.4) |
| R+/D− | 11/14 (78) | 4/9 (44) | 5/9 (55) | 1/14 (7.1) | 1 (7.1) | 3 (21.4) |
| R−/D+ | 4/8 (50) | 1/4 (25) | 2/4 (50) | 0/8 (0) | 1 (12.5) | 1 (12.5) |
| CMV serostatus . | CMV infection (%) . | Recurrence < 100 d (%) . | Recurrence > 100 d (%) . | CMV disease (%) . | Nonrelapse mortality . | |
|---|---|---|---|---|---|---|
| 100 d (%) . | Overall (%) . | |||||
| R+/D+ | 35/38 (92) | 16/27 (59) | 9/24 (41) | 2/38 (5.2) | 3 (7.8) | 7 (18.4) |
| R+/D− | 11/14 (78) | 4/9 (44) | 5/9 (55) | 1/14 (7.1) | 1 (7.1) | 3 (21.4) |
| R−/D+ | 4/8 (50) | 1/4 (25) | 2/4 (50) | 0/8 (0) | 1 (12.5) | 1 (12.5) |
The differences between these subgroups were not statistically significant (P > .05).